Nanocell targeting using engineered bispecific antibodies

mAbs

Volumn 7, Issue 1, 2015, Pages 53-65

  Taylor, Karin ^a   Howard, Christopher B ^a   Jones, Martina L ^a   Sedliarou, Ilya ^b   MacDiarmid, Jennifer ^b   Brahmbhatt, Himanshu ^b   Munro, Trent P ^a   Mahler, Stephen M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b EnGeneIC Ltd   (Australia)

Author keywords

Bispecific antibody; Disulfide bridge; Mammalian expression; Nanoparticle; Single chain Fv; Surface plasmon resonance; Tumor regression

Indexed keywords

BISPECIFIC ANTIBODY; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; GLYCINE; NANOCELL; NANOPARTICLE; SERINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; CANCER ANTIBODY; EGFR PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; CANCER REGRESSION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; INTERFEROMETRY; MOUSE; NONHUMAN; SURFACE PLASMON RESONANCE; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG SCREENING; FEMALE; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; NUDE MOUSE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921395881     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/19420862.2014.985952     Document Type: Article

References (82)

1. Burden RE, Caswell J, Fay F, Scott CJ. Recent advances in the application of antibodies as therapeutics. Future Med Chem 2012; 4:73-86; PMID:22168165; http://dx.doi.org/10.4155/fmc.11.165
2. Yoo J-W, Irvine DJ, Discher DE, Mitragotri S. Bioinspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 2011; 10:521-35; PMID:21720407; http://dx.doi.org/10.1038/nrd3499
3. Elvin JG, Couston RG, van der Walle CF. Therapeutic antibodies: Market considerations, disease targets and bioprocessing. Int J Pharm 2013; 440:83-98; PMID:22227342; http://dx.doi.org/10.1016/j.ijpharm.2011.12.039
4. Perchiacca JM, Ladiwala ARA, Bhattacharya M, Tessier PM. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng Des Sel 2012; 25:591-602; PMID:22843678; http://dx.doi.org/10.1093/protein/gzs042
5. Chames P, Baty D. Bispecific Single Domain Antibodies. New York: Springer, 2011.
6. Teillaud J-L. From whole monoclonal antibodies to single domain antibodies: think small. Methods Mol Biol 2012; 911:3-13.
7. Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today 2012; 17:954-63; PMID:22561895; http://dx.doi.org/10.1016/j.drudis.2012.04.006
8. Pasquetto MV, Vecchia L, Covini D, Digilio R, Scotti C. Targeted Drug Delivery Using Immunoconjugates: Principles and Applications. J Immunother 2011; 34:611-28; PMID:21989410; http://dx.doi.org/10.1097/CJI.0b013e318234ecf5
9. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, et al. MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006; 43:1129-43; PMID:16139892; http://dx.doi.org/10.1016/j.molimm.2005.07.034
10. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36; PMID:16151406; http://dx.doi.org/10.1038/nbt1142
11. Kontermann R. Dual targeting strategies with bispecific antibodies. mAbs 2012; 4:182-97; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
12. Zhu Z. Dual-Targeting Bispecific Antibodies as New Therapeutic Modalities for Cancer. In: Wood CR, ed. Antibody Drug Discovery. London, UK: Imperial College Press, 2011:373-408
13. May C, Sapra P, Gerber H-P. Advances in bispecific biotherapeutics for the treatment of cancer. Biochem Pharmacol 2012; 84:1105-12; PMID:22858161; http://dx.doi.org/10.1016/j.bcp.2012.07.011
14. Chames P, Baty D. Bispecific antibodies for cancer therapy The light at the end of the tunnel? MAbs 2009; 1:539-47; PMID:20073127; http://dx.doi.org/10.4161/mabs.1.6.10015
15. Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31:621-32; PMID:24094861; http://dx.doi.org/10.1016/j.tibtech.2013.08.007
16. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Nati Acad Sci U S A 2010; 107:12605-10; PMID:20616015; http://dx.doi.org/10.1073/pnas.1000976107
17. Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, et al. Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion. J Mol Biol 2010; 399:436-49; PMID:20382161; http://dx.doi.org/10.1016/j.jmb.2010.04.001
18. Atanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, et al. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Hum Vaccin Immunother 2013; 9:5-4; http://dx.doi.org/10.4161/hv.26065
19. Linke R, Klein A, Seimetz D. Catumaxomab: Clinical development and future directions. MAbs 2010; 2:129-36; PMID:20190561; http://dx.doi.org/10.4161/mabs.2.2.11221
20. Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2010; 2:309-19; PMID:20418662; http://dx.doi.org/10.4161/mabs.2.3.11791
21. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, Haasdyk JE, Dickson KA, Brahmbhatt VN, Pattison ST, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 2007; 11:431-45; PMID:17482133; http://dx.doi.org/10.1016/j.ccr.2007.03.012
22. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K, Brahmbhatt VN, Phillips L, Pattison ST, Petti C, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 2009; 27:643-51; PMID:19561595; http://dx.doi.org/10.1038/nbt.1547
23. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4:145-60; PMID:15688077; http://dx.doi.org/10.1038/nrd1632
24. Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 2005; 5:161-71; PMID:15738981; http://dx.doi.org/10.1038/nrc1566
25. Webster DM, Sundaram P, Byrne ME. Injectable nanomaterials for drug delivery: Carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm 2013; 84:1-20; PMID:23313176; http://dx.doi.org/10.1016/j.ejpb.2012.12.009
26. Couvreur P. Nanoparticles in drug delivery: Past, present and future. Adv Drug Deliv Rev 2013; 65:21-3; PMID:22580334; http://dx.doi.org/10.1016/j.addr.2012.04.010
27. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release 2012; 161:175-87; PMID:21945285; http://dx.doi.org/10.1016/j.jconrel.2011.09.063
28. Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 2013; 48:416-27; PMID:23262059; http://dx.doi.org/10.1016/j.ejps.2012.12.006
29. Battaglia DP. Targeted Drug Delivery. Amsterdam, Netherlands: Elsevier Science Bv, 2013.
30. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2007; 2:751-60; http://dx.doi.org/10.1038/nnano.2007.387.
31. MacDiarmid JA, Brahmbhatt H. Minicells: Versatile vectors for targeted drug or si/shRNA cancer therapy. Curr Opin Biotechnol 2011; 22:909-16; PMID:21550793; http://dx.doi.org/10.1016/j.copbio.2011.04.008
32. Felice B, Prabhakaran MP, Rodriguez AP, Ramakrishna S. Drug delivery vehicles on a nano-engineering perspective. Mater Sci Eng C-Mater Biol Appl 2014; 41:178-95; PMID:24907751; http://dx.doi.org/10.1016/j.msec.2014.04.049.
33. Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomed 2014; 9:467-83
34. Fay F, Scott CJ. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy 2011; 3:381-94; PMID:21395380; http://dx.doi.org/10.2217/imt.11.5
35. Geers B, De Wever O, Demeester J, Bracke M, De Smedt SC, Lentacker I. Targeted Liposome-Loaded Microbubbles for Cell-Specific Ultrasound-Triggered Drug Delivery. Small 2013; 9:4027-35; PMID:23737360; http://dx.doi.org/10.1002/smll.201300161
36. Yang LL, Mao H, Wang YA, Cao ZH, Peng XH, Wang XX, Duan HW, Ni CC, Yuan QG, Adams G, et al. Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in vivo Tumor Targeting and Imaging. Small 2009; 5:235-43; PMID:19089838; http://dx.doi.org/10.1002/smll.200800714
37. Goodall S, Howard CB, Jones ML, Munro T, Jia Z, Monteiro MJ, Mahler S. An EGFR Targeting Nanoparticle Self Assembled from a Thermoresponsive Polymer. J Chem Technol Biotechnol 2014; 10.1002/jctb.4509
38. Bertrand N, Wu J, Xu XY, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014; 66:2-25; PMID:24270007; http://dx.doi.org/10.1016/j.addr.2013.11.009
39. Ellerman D, Scheer JM. Generation of Bispecific Antibodies by Chemical Conjugation. New York: Springer, 2011
40. Holliger P, Prospero T, Winter G. DIABODIES - SMALL BIVALENT AND BISPECIFIC ANTIBODY FRAGMENTS. Proc Nati Acad Sci U S A 1993; 90:6444-8; PMID:8341653; http://dx.doi.org/10.1073/pnas.90.14.6444
41. Muller D, Kontermann RE. Diabodies, Single-Chain Diabodies, and Their Derivatives. New York: Springer, 2011.
42. Kontermann RE. Bispecific Antibodies. New York: Springer, 2011, 1-373.
43. Moore PA, Zhang WJ, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang YH, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011; 117:4542-51; PMID:21300981; http://dx.doi.org/10.1182/blood-2010-09-306449
44. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschlager M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010; 23:289-97; PMID:20150180; http://dx.doi.org/10.1093/protein/gzq005
45. Wang L, He YR, Zhang G, Ma J, Liu CZ, He W, Wang W, Han HM, Boruah BM, Gao B. Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody. PLoS ONE 2013; 8(9):e75589; PMID:24086580; doi:10.1371/journal.pone.0075589
46. Enever C, Batuwangala T, Plummer C, Sepp A. Next generation immunotherapeutics - honing the magic bullet. Curr Opin Biotechnol 2009; 20:405-11; PMID:19709876; http://dx.doi.org/10.1016/j.copbio.2009.07.002
47. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20:460-70; PMID:18656541; http://dx.doi.org/10.1016/j.coi.2008.06.012
48. Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, Henegouwen PVE. THE EPIDERMAL GROWTH-FACTOR. Cell Biol Int 1995; 19:413-30; PMID:7640657; http://dx.doi.org/10.1006/cbir.1995.1086
49. Grunwald V, Hidalgo M. The epidermal growth factor receptor: A new target for anticancer therapy. Curr Problems in Cancer 2002; 26:109-64; PMID:12085086; http://dx.doi.org/10.1067/mcn.2002.125874
50. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33:369-85; PMID:16890793; http://dx.doi.org/10.1053/j.seminoncol.2006.04.003
51. Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anti-Cancer Drugs 2007; 18:7-15; PMID:17159497; http://dx.doi.org/10.1097/CAD.0b013e32800feecb
52. Gemmete JJ, Mukherji SK. Panitumumab (Vectibix). Am J Neuroradiol 2011; 32:1002-3; PMID:21596817; http://dx.doi.org/10.3174/ajnr.A2601
53. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007; 25:1134-43; PMID:17921999; http://dx.doi.org/10.1038/nbt1337
54. Zhu JW. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 2012; 30:1158-70; PMID:21968146; http://dx.doi.org/10.1016/j.biotechadv.2011.08.022
55. Dinnis DM, James DC. Engineering mammalian cell factories for improved recombinant monoclonal antibody production: Lessons from nature? Biotechnol Bioeng 2005; 91:180-9; PMID:15880827; http://dx.doi.org/10.1002/bit.20499
56. Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, et al. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel 2012; 25:571-80; http://dx.doi.org/10.1093/protein/gzs064
57. Feige MJ, Groscurth S, Marcinowski M, Shimizu Y, Kessler H, Hendershot LM, Buchner J. An Unfolded C (H)1 Domain Controls the Assembly and Secretion of IgG Antibodies. Molecular Cell 2009; 34:569-79; PMID:19524537; http://dx.doi.org/10.1016/j.molcel.2009.04.028
58. Yang XD, Jia XC, Corvalan JRF, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999; 59:1236-43; PMID:10096554
59. Mendez MJ, Green LL, Corvalan JRF, Jia XC, MaynardCurrie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997; 15:146-56; PMID:9020839; http://dx.doi.org/10.1038/ng0297-146
60. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Nati Acad Sci U S A 1998; 95:4607-12; PMID:9539785; http://dx.doi.org/10.1073/pnas.95.8.4607
61. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54:3352-6; PMID:8012948
62. Reichert JM. Antibodies to watch in 2013: Mid-year update. MAbs 2013; 5:513-7; PMID:23727858; http://dx.doi.org/10.4161/mabs.24990
63. Merchant AM, Zhu ZP, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-81; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
64. Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, Stevens B, Julien S, Franke S, Meengs B, et al. A dual-targeting PDGFR beta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. mAbs 2010; 2:20-34; PMID:20065654; http://dx.doi.org/10.4161/mabs.2.1.10498
65. Ridgway JBB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody C(H)3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617
66. Zhu ZP, Presta LG, Zapata G, Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997; 6:781-8; PMID:9098887; http://dx.doi.org/10.1002/pro.5560060404
67. Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol 2008; 20:479-85; PMID:18577454; http://dx.doi.org/10.1016/j.coi.2008.05.010
68. Jendreyko N. Intradiabodies, Bispecific, Tetravalent Antibodies for the Simultaneous Functional Knockout of Two Cell Surface Receptors. J Biol Chem 2003; 278:47812-9; PMID:12947084; http://dx.doi.org/10.1074/jbc.M307002200
69. Abou-Nassar K, Brown JR. Novel agents for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol : H&O 2010; 8:886-95.
70. Lee CC, Perchiacca JM, Tessier PM. Toward aggregation-resistant antibodies by design. Trends Biotechnol 2013; 31:612-20; PMID:23932102; http://dx.doi.org/10.1016/j.tibtech.2013.07.002
71. Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu XF, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; PMID:20457695; http://dx.doi.org/10.1093/protein/gzq028
72. Demarest SJ, Glaser SM. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Dev 2008; 11:675-87.
73. Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, Zhang J, Hoffmann E, Dormeyer W, Stracke J, et al. Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains. Antimicrob Agents Chemother 2011; 55:2369-78; PMID:21300827; http://dx.doi.org/10.1128/AAC.00215-10
74. Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, Brender T, Okada S, Lum K, West J, et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Design Sel 2009; 23:115-27; http://dx.doi.org/10.1093/protein/gzp073
75. Moore GL, Bautista C, Pong E, Nguyen D-HT, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY, Lazar GA. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. mAbs 2011; 3:546-57; PMID:22123055; http://dx.doi.org/10.4161/mabs.3.6.18123
76. McAleese F, Eser M. RECRUIT-TandAbs (R): harnessing the immune system to kill cancer cells. Future Oncol 2012; 8:687-95; PMID:22764766; http://dx.doi.org/10.2217/fon.12.54
77. Rajkovic E, Hucke C, Knackmuss S, Molkenthin V, Reusch U, Legall F, Little M. Recruit-TandAbs: Engaging immune cells to kill cancer cells AFM13: A bispecific tetravalent TandAb for treating Hodgkin Lymphoma. 11th International Conference on Malignant Lymphoma 15-18 June 2011. Lugano (Switzerland): Ann Oncol 2011:240-1
78. Adams TE, Koziolek EJ, Hoyne PH, Bentley JD, Lu L, Lovrecz G, Ward CW, Lee FT, Scott AM, Nash AD, et al. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo. Growth Factors 2009; 27:141-54; PMID:19333814; http://dx.doi.org/10.1080/08977190902843565
79. Morrison SL. Cloning, expression, and modification of antibody V regions. Curr Proto Immunol 2002; Chapter 2:Unit 2.12; PMID:18432877; doi:10.1002/0471142735.im0212s47
80. Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270:26-35; PMID:9231898; http://dx.doi.org/10.1006/jmbi.1997.1116
81. Jones ML, Seldone T, Smede M, Linville A, Chin DY, Barnard R, Mahler SM, Munster D, Hart D, Gray PP, et al. A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. J Immunol Methods 2010; 354:85-90; PMID:20153332; http://dx.doi.org/10.1016/j.jim.2010.02.001
82. Codamo J, Hou JJC, Hughes BS, Gray PP, Munro TP. Efficient mAb production in CHO cells incorporating PEI-mediated transfection, mild hypothermia and the co-expression of XBP-1. J Chem Technol Biotechnol 2011; 86:923-34; http://dx.doi.org/10.1002/jctb.2572